Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods : We analyzed 119 advanced BTC patients w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hongsik Kim MD, Hana Kim MD, Ryul Kim MD, PhD, Hyunji Jo MD, Hye Ryeon Kim MD, Joohyun Hong MD, PhD, Joon Oh Park MD, PhD, Young Suk Park MD, PhD, Seung Tae Kim MD, PhD
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/83fd42d3d7f54068817202539c732b95
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83fd42d3d7f54068817202539c732b95
record_format	dspace
spelling	oai:doaj.org-article:83fd42d3d7f54068817202539c732b952021-12-03T00:03:19ZTumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer1533-033810.1177/15330338211062324https://doaj.org/article/83fd42d3d7f54068817202539c732b952021-12-01T00:00:00Zhttps://doi.org/10.1177/15330338211062324https://doaj.org/toc/1533-0338Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods : We analyzed 119 advanced BTC patients who received Gemcitabine/Cisplatin (GP) as a first-line treatment between November 2019 and April 2021. Next-generation sequencing (NGS), including TMB analysis, as a routine clinical practice was performed in 119 patients. The TruSight TM Oncology 500 assay from Illumina was used as a cancer panel. Results : Among 119 patients, 18 (18.5%) had a tumor with high TMB (≥ 10 Muts/Mb). There were no significant differences between the status of TMB and clinical outcomes with GP, including objective response rate (ORR) ( P = .126), disease control rate (DCR) ( p = .454), and median progression-free survival (PFS) ( p = .599). The median overall survival (OS) was not different between patients with TMB-H and no TMB-H ( p = .430). In subgroup analysis of 32 patients receiving immune checkpoint inhibitor (ICIs), there were significant differences in ORR ( p = .034) and median PFS ( p = .025) with ICIs between patients with and without TMB-H. Conclusions : This study revealed that TMB-H in advanced BTCs did not have a prognostic or role in the standard first-line treatment. However, TMB-H might be a predictive biomarker for response to ICIs in advanced BTC.Hongsik Kim MDHana Kim MDRyul Kim MD, PhDHyunji Jo MDHye Ryeon Kim MDJoohyun Hong MD, PhDJoon Oh Park MD, PhDYoung Suk Park MD, PhDSeung Tae Kim MD, PhDSAGE PublishingarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENTechnology in Cancer Research & Treatment, Vol 20 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Hongsik Kim MD Hana Kim MD Ryul Kim MD, PhD Hyunji Jo MD Hye Ryeon Kim MD Joohyun Hong MD, PhD Joon Oh Park MD, PhD Young Suk Park MD, PhD Seung Tae Kim MD, PhD Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
description	Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods : We analyzed 119 advanced BTC patients who received Gemcitabine/Cisplatin (GP) as a first-line treatment between November 2019 and April 2021. Next-generation sequencing (NGS), including TMB analysis, as a routine clinical practice was performed in 119 patients. The TruSight TM Oncology 500 assay from Illumina was used as a cancer panel. Results : Among 119 patients, 18 (18.5%) had a tumor with high TMB (≥ 10 Muts/Mb). There were no significant differences between the status of TMB and clinical outcomes with GP, including objective response rate (ORR) ( P = .126), disease control rate (DCR) ( p = .454), and median progression-free survival (PFS) ( p = .599). The median overall survival (OS) was not different between patients with TMB-H and no TMB-H ( p = .430). In subgroup analysis of 32 patients receiving immune checkpoint inhibitor (ICIs), there were significant differences in ORR ( p = .034) and median PFS ( p = .025) with ICIs between patients with and without TMB-H. Conclusions : This study revealed that TMB-H in advanced BTCs did not have a prognostic or role in the standard first-line treatment. However, TMB-H might be a predictive biomarker for response to ICIs in advanced BTC.
format	article
author	Hongsik Kim MD Hana Kim MD Ryul Kim MD, PhD Hyunji Jo MD Hye Ryeon Kim MD Joohyun Hong MD, PhD Joon Oh Park MD, PhD Young Suk Park MD, PhD Seung Tae Kim MD, PhD
author_facet	Hongsik Kim MD Hana Kim MD Ryul Kim MD, PhD Hyunji Jo MD Hye Ryeon Kim MD Joohyun Hong MD, PhD Joon Oh Park MD, PhD Young Suk Park MD, PhD Seung Tae Kim MD, PhD
author_sort	Hongsik Kim MD
title	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
title_short	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
title_full	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
title_fullStr	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
title_full_unstemmed	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
title_sort	tumor mutational burden as a biomarker for advanced biliary tract cancer
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/83fd42d3d7f54068817202539c732b95
work_keys_str_mv	AT hongsikkimmd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT hanakimmd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT ryulkimmdphd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT hyunjijomd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT hyeryeonkimmd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT joohyunhongmdphd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT joonohparkmdphd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT youngsukparkmdphd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer AT seungtaekimmdphd tumormutationalburdenasabiomarkerforadvancedbiliarytractcancer
_version_	1718373999013003264

Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer

Ejemplares similares